← Leaderboards
Erkang Fan
University Of Washington
$6,366,172
Attributed
$11,297,944
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $814.3K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,297,944 · 4
By mechanism
R01$11,297,944 · 4
Top collaborators
- Frederick Simmons Buckner12 shared
- Kayode K Ojo2 shared
Most similar at University Of Washington
Same institution · by research overlap
- Frederick Simmons Buckner$14,937,505
- Kayode K Ojo$5,773,228
- Wilhelmus G. J. Hol$41,011,333
- Michael H Gelb$24,827,130
- Alexander Richard Paredez$5,038,624
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsPharmaceutical PreparationsDrug KineticsGrowthOralEnzymesDesignParasitesLeadMammalian CellToxic EffectAnalogCytotoxicityPre-ClinicalInfectionPharmacology And ToxicologyMethionine-Trna LigaseAfrican TrypanosomiasisNovel TherapeuticsIterative DesignBackEnzyme Inhibitor DrugsParasitic DiseasesIn Vitro Assay
Grant awards (19)
Development of dual effective kinase inhibitors as syndromic treatment of Giardiasis and Cryptosporidiosis$746,285
R01 · FY2025 · AI
Development of dual effective kinase inhibitors as syndromic treatment of Giardiasis and Cryptosporidiosis$769,365
R01 · FY2024 · AI
Developing methionyl tRNA synthetase inhibitors as therapeutics for Chagas disease$814,270
R01 · FY2023 · AI · contact PI
Developing methionyl tRNA synthetase inhibitors as therapeutics for Chagas disease$772,120
R01 · FY2022 · AI · contact PI
Developing methionyl tRNA synthetase inhibitors as therapeutics for Chagas disease$733,618
R01 · FY2021 · AI · contact PI
Developing methionyl tRNA synthetase inhibitors as therapeutics for Chagas disease$733,618
R01 · FY2020 · AI · contact PI
Optimization of methionyl-tRNA synthetase inhibitors for human African trypanosomiasis$696,541
R01 · FY2019 · AI · contact PI
Optimization of methionyl-tRNA synthetase inhibitors for human African trypanosomiasis$698,131
R01 · FY2018 · AI · contact PI
Optimization of methionyl-tRNA synthetase inhibitors for human African trypanosomiasis$709,649
R01 · FY2017 · AI · contact PI
Optimization of methionyl-tRNA synthetase inhibitors for human African trypanosomiasis$735,148
R01 · FY2016 · AI · contact PI
Structure-based Optimization of T. brucei methionyl tRNA Synthetase Inhibitors$611,718
R01 · FY2015 · AI · contact PI
Structure-based Optimization of T. brucei methionyl tRNA Synthetase Inhibitors$634,893
R01 · FY2014 · AI · contact PI
Structure-based Optimization of T. brucei methionyl tRNA Synthetase Inhibitors$596,800
R01 · FY2013 · AI · contact PI
Structure-based Optimization of T. brucei methionyl tRNA Synthetase Inhibitors$611,388
R01 · FY2012 · AI · contact PI
MULTIDENTATE HIGH AFFINITY LIGANDS FOR AB5 TOXINS$301,784
R01 · FY2004 · AI
MULTIDENTATE HIGH AFFINITY LIGANDS FOR AB5 TOXINS$293,082
R01 · FY2003 · AI
MULTIDENTATE HIGH AFFINITY LIGANDS FOR AB5 TOXINS$284,634
R01 · FY2002 · AI
MULTIDENTATE HIGH AFFINITY LIGANDS FOR AB5 TOXINS$281,432
R01 · FY2001 · AI
MULTIDENTATE HIGH AFFINITY LIGANDS FOR AB5 TOXINS$273,468
R01 · FY2000 · AI